More Uncertainty About Platinum Chemotherapy for BRCA-Associated Breast Cancers

Pathologic complete response was not improved with cisplatin versus doxorubicin and cyclophosphamide.

The role of platinum-based chemotherapy for BRCA-mutated breast cancer and triple-negative breast cancer (TNBC) remains a subject of debate. Trials such as TNT (Nat Med 2018; 24:628) showed that a platinum agent (carboplatin) offered a clinical advantage over a taxane (docetaxel) in patients with BRCA-associated TNBC, but not in other TNBC patients. However, findings from the GeparSixto trial (NEJM JW Oncol Hematol Sep 2014 and Lancet Oncol 2014 Jun; 15:747 and NEJM JW Oncol Hematol Sep 2017 and JAMA Oncol 2017; 3:1378) showed that adding a platinum agent (carboplatin) to neoadjuvant therapy containing a taxane (paclitaxel), an anthracycline (doxorubicin), and an antiangiogenic agent (bevacizumab) did not significantly improve pathologic co…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)

More Uncertainty About Platinum Chemotherapy for BRCA-Associated Breast Cancers

Topics

Reviewing Author